Fortis Malar Hospitals Limited announced its unaudited financial results for the quarter ended December 31, 2025, along with key board appointments during a meeting held on February 6, 2026. The company reported improved financial performance despite operating without active business operations following the earlier sale of its hospital business.

Financial Performance Highlights

The company's standalone financial results showed positive growth across key metrics for the third quarter of FY26:

For the nine months ended December 31, 2025, the company reported exceptional performance with a standalone net profit of ₹423.24 crores compared to ₹4.83 crores in the corresponding period of the previous year. The significant improvement was primarily driven by other income of ₹564.55 crores, which included a provision reversal of ₹408.20 lakhs related to minimum wage rates following a government notification.

Board Leadership Changes

The Board of Directors approved two significant appointments subject to shareholder approval:

Leadership Profiles

Bidesh Chandra Paul brings over 15 years of healthcare and operations experience to his new role. He holds dual degrees from IIT Kharagpur and a Post Graduate Programme from IIM Bangalore. Since joining Fortis in August 2019, he has driven significant strategic outcomes, including delivering 31% revenue growth over four years at Fortis Heart Institute, Okhla and transforming the previously loss-making CDC into an EBITDA-neutral hospital.

Shailaja Chandra contributes over 20 years of health sector experience, having served as Secretary in the Ministry of Health & Family Welfare, Government of India, and as Delhi's Chief Secretary. Her 38-year civil service career included postings with the Ministries of Defence, Power and Health, along with various post-retirement executive assignments.

Current Business Status

The company continues to operate without active business operations following the sale of its hospital business through a slump sale transaction to MGM Healthcare Private Limited during the year ended March 31, 2024. The management is currently evaluating various corporate restructuring options for future strategic directions.

Financial Position and Outlook

Despite the absence of operational business, Fortis Malar Hospitals maintains a strong financial position with cash and cash equivalents of approximately ₹3,251.64 lakhs. The company believes this liquidity is sufficient to meet ongoing obligations, including potential settlements related to medico-legal cases, VAT appeals, GST appeals, and income tax appeals currently being contested.

The auditors B S R & Co. LLP issued unmodified limited review reports for both standalone and consolidated financial results, confirming the preparation on a going concern basis. The paid-up equity share capital remains unchanged at ₹1,875.70 crores with a face value of ₹10 per share.

Fortis Malar Hospitals Limited has issued an official clarification to BSE Limited regarding an erroneous regulatory filing that was inadvertently reported under the company's name on January 2, 2026.

Filing Details and Clarification

The clarification, dated January 7, 2026, addresses a specific announcement that was titled "Disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)". According to the company's communication to BSE, this announcement was mistakenly attributed to Fortis Malar Hospitals Limited when it actually pertains to another group company.

Company Communication

The clarification was signed by Vinti Verma, Company Secretary & Compliance Officer (Membership No.: A44528), who digitally signed the document on January 7, 2026. The company has specifically requested shareholders to ignore the January 2, 2026 announcement as it does not relate to Fortis Malar Hospitals Limited's operations or disclosures.

Regulatory Context

The erroneous filing was originally categorized under Regulation 30 of SEBI Listing Regulations, which governs disclosure of material events and information by listed companies. Such clarifications are important for maintaining transparency and ensuring that investors have accurate information about the company's actual disclosures and material events.

Shareholder Advisory

Fortis Malar Hospitals Limited has advised its shareholders to disregard the January 2, 2026 announcement entirely. The company emphasized that this clarification serves as official information for shareholders' records and requested them to treat only legitimate company announcements as valid disclosures going forward.